|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-2.59/-0.95
|
企业价值
67.66M
|
资产负债 |
每股账面净值
0.64
|
现金流量 |
现金流量率
--
|
损益表 |
收益
14.92M
|
每股收益
0.08
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/05/05 01:44 EDT
同行比较之报价最少15分钟延迟
业务概览
|
|||
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells. |